Grant: Project Grant

Glioblastoma (GBM) is a highly aggressive type of brain cancer with a very poor prognosis, often resistant to existing treatments. These tumors are particularly challenging to treat due to their rapid growth, genetic complexity, and the presence of the blood-brain barrier (BBB), preventing most drugs to reach the brain. This research is exploring a new approach called targeted radioligand therapy, which combines the precision of molecular targeting of APJ receptors expressed by GBM with the power of radiation therapy using brain-penetrating apelin theranostic probes. By creating molecules that can both target cancer cells and cross the BBB to deliver radiation directly to the tumor, we aim to develop a treatment option that is more effective and less toxic than current options. This research could lead to novel treatment options for GBM patients, offering hope for improved survival and better quality of life.